Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL

Apr 18, 2023 | Press Releases

– Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 – MARLBOROUGH, Mass., April 18, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™...

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity

Apr 17, 2023 | Press Releases

– Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 – MARLBOROUGH, Mass., April 17, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™...

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

Mar 22, 2023 | Press Releases

– Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma – – Received confirmation from the FDA that the planned Phase 1 clinical trial in patients...

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

Feb 22, 2023 | Press Releases

MARLBOROUGH, Mass., Feb. 22, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Feb 13, 2023 | Press Releases

MARLBOROUGH, Mass., Feb. 13, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...